Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice

Cardiovascular Research

Volumn 84, Issue 1, 2009, Pages 164-172

  Hirata, Ayumu ^a   Maeda, Norikazu ^a   Hiuge, Aki ^a   Hibuse, Toshiyuki ^a   Fujita, Koichi ^a   Okada, Takuya ^a   Kihara, Shinji ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipose tissue; Inflammation; Insulin resistance; Mineralocorticoid receptor; Oxidative stress

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ALDOSTERONE; EPLERENONE; HYDROGEN PEROXIDE; INTERLEUKIN 6; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; REACTIVE OXYGEN METABOLITE; RECOMBINANT HUMAN INSULIN; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1; DRUG DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; SPIRONOLACTONE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; GENE CONTROL; GENE EXPRESSION; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CELL STRAIN 3T3; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NADPH OXIDASE; OBESITY; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; RNA, SMALL INTERFERING; SPIRONOLACTONE;

EID: 70449718904     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp191     Document Type: Article

References (37)

1. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006;444:847-853.
2. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
3. Lehrke M, Lazar MA. Inflamed about obesity. Nat Med 2004;10:126-127.
4. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444: 860-867.
5. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
6. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
7. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
8. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008;51:1252-1258.
9. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004;110: 1507-1512.
10. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006;70:1717-1724.
11. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S et al. Aldoster-one activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005;45:773-779.
12. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Yet al. Car-dioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006;47:671-679.
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Epler-enone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321.
15. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR et al. Miner-alocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008;117: 2253-2261.
16. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004;109:2213-2220.
17. Zhang Q, Saito Y, Naya N, Imagawa K, Somekawa S, Kawata H et al. The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A. Hypertens Res 2008;31:1251-1256.
18. Ahras M, Naing T, McPherson R. Scavenger receptor class B type I localizes to a late endosomal compartment. J Lipid Res 2008;49:1569-1576.
19. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H et al. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes 2007;56: 1517-1526.
20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
21. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007;50:750-755.
22. Moore XL, Tan SL, Lo CY, Fang L, Su YD, Gao XM et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007;148:1582-1589.
23. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H et al. Diet-induced insulin resistance in mice lacking adiponectin/ ACRP30. Nat Med 2002;8:731-737.
24. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-184.
25. Li SL, Valente AJ, Zhao SJ, Clark RA. PU.1 is essential for p47(phox) promoter activity in myeloid cells. J Biol Chem 1997;272:17802-17809.
26. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007;5:e012.
27. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51:161-167.
28. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293: H2009-H2023.
29. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K et al. Troglita-zone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101: 1354-1361.
30. Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci 2006;1083:165-184.
31. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.
32. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931-938.
33. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 2008;86:729-734.
34. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A et al. Human adipocytes secrete mineralocorticoid- releasing factors. Proc Natl Acad Sci USA 2003;100: 14211-14216.
35. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994;7:886-893.
36. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004;109:2792-2800.
37. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007;292:E1280-E1287.